Designing type V deep eutectic solvents with antimalarial pharmaceutical ingredients.

Autor: Teixeira G; CICECO, Aveiro Institute of Materials, Complexo de Laboratórios Tecnológicos, University of Aveiro, Campus Universitário de Santiago, Aveiro, Portugal., Brandão P; CICECO, Aveiro Institute of Materials, Complexo de Laboratórios Tecnológicos, University of Aveiro, Campus Universitário de Santiago, Aveiro, Portugal., Lobo Ferreira AIMC; CIQUP, Institute of Molecular Sciences (IMS), Departamento de Química e Bioquímica, Faculdade de Ciências da Universidade do Porto, Rua Campo Alegre 4169-007, Porto, Portugal., Abranches DO; CICECO, Aveiro Institute of Materials, Complexo de Laboratórios Tecnológicos, University of Aveiro, Campus Universitário de Santiago, Aveiro, Portugal., Santos LMNBF; CIQUP, Institute of Molecular Sciences (IMS), Departamento de Química e Bioquímica, Faculdade de Ciências da Universidade do Porto, Rua Campo Alegre 4169-007, Porto, Portugal., Ferreira O; Centro de Investigação de Montanha (CIMO), Instituto Politécnico de Bragança, Campus de Santa Apolónia, 5300-253, Bragança, Portugal; Laboratório para a Sustentabilidade e Tecnologia em Regiões de Montanha, Instituto Politécnico de Bragança, Campus de Santa Apolónia, 5300-253, Bragança, Portugal. Electronic address: oferreira@ipb.pt., Coutinho JAP; CICECO, Aveiro Institute of Materials, Complexo de Laboratórios Tecnológicos, University of Aveiro, Campus Universitário de Santiago, Aveiro, Portugal.
Jazyk: angličtina
Zdroj: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V [Eur J Pharm Biopharm] 2024 Oct; Vol. 203, pp. 114463. Date of Electronic Publication: 2024 Aug 27.
DOI: 10.1016/j.ejpb.2024.114463
Abstrakt: This work studies the formation of deep eutectic solvents formed by one active pharmaceutical ingredient (quinine, pyrimethamine, or 2-phenylimidazopyridine) and a second component potentially acting as an excipient (betaine, choline chloride, tetramethylammonium chloride, thymol, menthol, gallic acid, vanillin, acetovanillone, 4-hydroxybenzaldehyde, syringaldehyde, propyl gallate, propylparaben, or butylated hydroxyanisole), aiming to address challenges regarding drug solubility, bioavailability, and permeability. A preliminary screening was carried out using the thermodynamic model COSMO-RS, narrowing down the search to three promising excipients (thymol, propyl gallate, and butylated hydroxyanisole). Nine solid-liquid equilibrium (SLE) phase diagrams were experimentally measured combining the three model drugs with the screened excipients, and using a combination of a visual melting method and differential scanning calorimetry. Negative deviations from thermodynamic ideality were observed in all nine systems. Furthermore, a total of four new cocrystals were found, with powder and single crystal X-ray diffraction techniques being employed to verify their unique diffraction patterns. In the thermodynamic modelling of the SLE diagrams, two COSMO-RS parametrizations (TZVP and TZVPD-FINE) were also applied, though neither consistently delivered a better description over the other.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: